A 77-year-old man with a malignant pleural effusion was treated by aspiration of fluid and injection of Corynbacterium parvum vaccine for pleurodesis. Within 24 hr he had developed a temperature and a neutropenia followed by an acute crippling polyarthritis of his hands and wrists which subsequently responded to oral steroids and non-steroidal antiinflammatory drugs.
Introduction
Rapid reaccumulation of fluid in malignant pleural effusion is a well-recognized clinical problem for which there is no completely successful therapy. Corynebacterium parvum vaccine (Coparvax) has been shown to be a useful agent for malignant effusions, its effect being thought to be a combination of chemical irritation combined with potent immunologic stimulation. The side effects reported to date have been minimal (Millar, Hunter and Home, 1980 A neutropenia (16% of a total white cell count of 66 x 109/litre) was noted. Rheumatoid factor, antinuclear factor and other autoantibody tests were negative. Viral titres to influenza, adenovirus, respiratory syncytial virus, mumps, mycoplasma, EpsteinBarr virus and Coxsackie B1-B6 were all negative. Circulating immune complexes were not sought.
There was no evidence of focal or systemic sepsis and this was presumed to be an acute reaction to the Coparvax. Treatment with indomethacin and prednisone, 30 mg per day, was commenced following which the symptoms of neutropaenia and synovitis disappeared. At follow-up, there was no evidence of soft tissue swelling at any joint and there was a full range of movement. He was subsequently treated with chemotherapy which he tolerated well.
Discussion
Coparvax has been shown to inhibit tumour growth in animals (Halpern, Biozzi and Stiffel, 1966) , and to stimulate macrophage function and phagocytosis and decrease the proliferative response of lymphocytes to common antigens (phytohaemagglutinin, pokeweed mitogen, concanavalin A) (Hilal et al., 1981) .
Clinical reports
Side effects described in the past have been maximal when the intravenous route has been used for its administration. These include nausea, vomiting, pyrexia, hypertension, diarrhoea, chest pain, peripheral cyanosis, headaches and transient elevation of liver enzymes (Gall et al., 1978) . Polyarthritis has not been previously described, but a large dose of bacterial antigen such as this might be suspected to be capable of producing an immune complexmediated arthritis, or, with its wide ranging immunological effects, precipitate a polyarthritis in a predisposed individual. Indeed, it has been suggested that Coparvax may be contraindicated in a patient with an auto-immune predisposition (Dorr and Fritz, 1980) .
With increasing use of Coparvax for malignant effusion, it is important to be aware of this possible adverse effect and its eminently treatable nature.
Confusion with hypertrophic pulmonary osteoar thropathy is also a possibility.
